These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2909287)

  • 1. Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model.
    Vaughan WP; Holm C; Cordel K
    Cancer Chemother Pharmacol; 1989; 23(1):26-30. PubMed ID: 2909287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells.
    Minford J; Kerrigan D; Nichols M; Shackney S; Zwelling LA
    Cancer Res; 1984 Dec; 44(12 Pt 1):5583-93. PubMed ID: 6208999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
    Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
    Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic action of high-dose hydroxyurea when used with cyclophosphamide and certain new organoplatinum complexes in treatment of advanced L1210 leukemia.
    Gale GR; Atkins LM; Meischen SJ; Schwartz P
    Cancer; 1978 Apr; 41(4):1230-4. PubMed ID: 638988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA).
    Bakic M; Beran M; Andersson BS; Silberman L; Estey E; Zwelling LA
    Biochem Biophys Res Commun; 1986 Jan; 134(2):638-45. PubMed ID: 3004458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
    Legha SS; Keating MJ; Zander AR; McCredie KB; Bodey GP; Freireich EJ
    Ann Intern Med; 1980 Jul; 93(1):17-21. PubMed ID: 6930826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
    Vaughan WP; Burke PJ
    Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.
    Freund M; Giller S; Hinrichs F; Baars A; Meran J; Körfer A; Link H; Poliwoda H
    J Cancer Res Clin Oncol; 1991; 117(5):489-92. PubMed ID: 1890142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intercalator-induced, topoisomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites.
    Zwelling LA; Silberman L; Estey E
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1041-7. PubMed ID: 2427489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
    Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
    Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia.
    Odaimi M; Andersson BS; McCredie KB; Beran M
    Cancer Res; 1986 Jul; 46(7):3330-3. PubMed ID: 3754787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
    Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group.
    Kahn SB; Spiers A; Knospe WH; Soojian M; Glick JH
    Am J Clin Oncol; 1987 Feb; 10(1):78-81. PubMed ID: 2435142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
    Currie VE; Howard J; Wittes R
    Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs.
    Estey EH; Silberman L; Beran M; Andersson BS; Zwelling LA
    Biochem Biophys Res Commun; 1987 Apr; 144(2):787-93. PubMed ID: 3034264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures.
    Wilson WR; Giesbrecht JL; Hill RP; Whitmore GF
    Cancer Res; 1981 Jul; 41(7):2809-16. PubMed ID: 6894713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
    Woodcock TM; Schneider RJ; Young CW
    Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin.
    Zwelling LA; Michaels S; Erickson LC; Ungerleider RS; Nichols M; Kohn KW
    Biochemistry; 1981 Nov; 20(23):6553-63. PubMed ID: 6895473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Case of refractory acute myeloblastic leukemia who achieved complete remission by a new anti-leukemic agent, 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA)].
    Nagura E; Kawashima K; Suzuki H; Ohno R; Yamada K; Yokomaku S; Ogawa M
    Rinsho Ketsueki; 1983 May; 24(5):632-8. PubMed ID: 6577212
    [No Abstract]   [Full Text] [Related]  

  • 20. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
    Adlakha RC; Ashorn CL; Chan D; Zwelling LA
    Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.